The ability to control and cure this disease has been limited so far.
But a study led by Drs. Przemyslaw (Mike) Sapieha and Frédérick A.
Mallette, researchers at Hôpital Maisonneuve-Rosemont (CIUSSS de
l’Est-de-l’Île-de-Montréal) and professors at the Université de
Montréal, sheds new understanding on the mechanisms of the disease as it
uncovered a program of accelerated aging of the neurons, blood vessels
and immune cells of the retina in areas where blood vessels had been
damaged. Dr. Malika Oubaha, postdoctoral fellow in Sapieha and
Mallette's group, found that cells of the retina that are cut off from
their main source of oxygen and nutrients during disease are resilient
and do not die. Instead, they enter a state of cellular senescence (or
cellular aging) where they are dormant yet start producing a series of
factors that contribute the blinding disease.
Their exciting work lead to the successful mapping and identification of the molecules that are activated during this process of premature aging. Interfering with the early cellular aging process occurring in mouse models of retinopathy with currently available and novel drugs resulted in improved regeneration of blood vessels within the retina and reduced retinal damage.
“Currently available treatments for diabetic retinopathy are either invasive or present adverse side effects when used for long term regimens. Our study does not identify a cure, but by mapping out the events that lead to premature senescence in retinopathy, we are now able to consider novel therapeutic interventions to slow down the disease process and preserve vision“, says Mike Sapieha.
Their exciting work lead to the successful mapping and identification of the molecules that are activated during this process of premature aging. Interfering with the early cellular aging process occurring in mouse models of retinopathy with currently available and novel drugs resulted in improved regeneration of blood vessels within the retina and reduced retinal damage.
“Currently available treatments for diabetic retinopathy are either invasive or present adverse side effects when used for long term regimens. Our study does not identify a cure, but by mapping out the events that lead to premature senescence in retinopathy, we are now able to consider novel therapeutic interventions to slow down the disease process and preserve vision“, says Mike Sapieha.
The hope
Ultimately, this study identifies potential therapeutic
avenues to prevent entry in the dormant senescent state of retina that
occurs during diseases such as diabetic retinopathy and help reinstate
adequate function of the retina.